DECREASED BENZODIAZEPINE BINDING WITH LITTLE EFFECT ON GAMMA-AMINOBUTYRIC-ACID BINDING IN RAT-BRAIN AFTER TREATMENT WITH ANTISENSE OLIGODEOXYNUCLEOTIDE TO THE GAMMA-AMINOBUTYRIC ACID(A) RECEPTOR GAMMA-2 SUBUNIT
Tj. Zhao et al., DECREASED BENZODIAZEPINE BINDING WITH LITTLE EFFECT ON GAMMA-AMINOBUTYRIC-ACID BINDING IN RAT-BRAIN AFTER TREATMENT WITH ANTISENSE OLIGODEOXYNUCLEOTIDE TO THE GAMMA-AMINOBUTYRIC ACID(A) RECEPTOR GAMMA-2 SUBUNIT, The Journal of pharmacology and experimental therapeutics, 287(2), 1998, pp. 752-759
Benzodiazepine potentiation of gamma-aminobutyric acid (GABA) neurotra
nsmission is associated with the presence of a gamma-2 subunit in the
GABA(A) receptor. A method was developed to modify the gamma-2 subunit
expression in adult rat brain. Unilateral intracerebroventricular (i.
c.v.) infusion of a 17-base phosphorothioate-modified antisense oligod
eoxynucleotide (ASO) was performed every 12 hr for 3 days. Controls we
re treated with a sense oligodeoxynucleotide. Parasagittal brain secti
ons were used for quantitative autoradiographic analysis of radioligan
d binding. ASO treatment caused a 15% to 25% decrease of specific [H-3
]flunitrazepam binding in most brain areas, with statistically signifi
cant decreases in frontal cortex, cerebellar molecular layer, zona ret
iculata of substantia nigra and CA3 of hippocampus. In contrast, [H-3]
muscimol binding was not changed. [H-3]GABA binding was also unchanged
, except for a 10% decrease in cerebellar granule cell layer. The effe
ct on the chloride channel of the GABA(A) receptor complex was examine
d by ethynyl-4-n-[2,3-H-3(2)]propylbicycloorthobenzoate binding; most
brain areas showed small decreases in ethynyl-4-n-[2,3-H-3(2)]propylbi
cycloorthobenzoate binding. However, hippocampal regions showed much l
arger decreases, Binding of the adenosine A(1) receptor antagonist [H-
3]8-cyclopentyl-1,3-dipropylxanthine was used to examine possible seco
ndary effects of the ASO. There was a decrease in [H-3]8-cyclopentyl-1
,3-dipropylxanthine binding, but this was much smaller than the change
in [H-3]flunitrazepam binding, and no area showed a significant effec
t. Quantitative immunoblotting with a monoclonal antibody that recogni
zes GABA(A) receptor beta-2 and beta-3 subunits showed no change in im
munoreactivity in cerebellar tissue after ASO treatment. The results i
ndicate a selective effect on benzodiazepine binding to GABA(A) recept
ors and a possible change in receptor subunit composition.